I am not an employee of the company, just someone with a degree in molecular bio. In my opinion their experimental design is inherently flawed, and their marketing department is awful.
However, I bought in on this stock a few days ago when it was .18-.19 because I see some potential, and it's pretty dirt cheap for a high risk gamble.
Bad news: there is nothing new that we don't already know.
The good news: The research revealed an unintended purpose to prevent metastatic cancer (cancer cell spread throughout the body) as opposed to treating late stage metastasis (if $ARGS haven't realize it yet). FDA is still keeping this drug around as a result of the potential long term therapeutic value (18+ months).
They should have made this a preventive therapy for metastatic cancer from the get go instead of trying to treat the metastasis in the late stage of cancer. When cancer is at that stage, only Jesus can help you. The risk for failure will be lower, and the investors would have bought in to it more.
